ArticleLung India : official organ of Indian Chest Society2025
Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months.
Article in Lung India : official organ of Indian Chest Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026Review
- Incidence and associated risk factors of anti-tuberculosis drug induced liver injury among TB patients.BMC infectious diseases · 2025Article
- Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named "Regimen C" for pre-XDR tuberculosis in Niger.Frontiers in tuberculosis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractTuberculosis (TB) is a global threat to public health and remains the second leading infectious cause of death from a single infectious agent in 2022. According to the global tuberculosis report 2023, an estimated 10.6 million people developed TB in 2022 and 1.3 million died from the disease. About 4,10,000 new cases of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) emerged in 2022. This huge burden has been recognised by World Health Organisation (WHO) by launching the End-TB strategy. The United Nations (UN) is committed to end TB epidemic globally by the year 2030; the aim is to reduce TB incidence by 80% and TB deaths by 90%. To eliminate the catastrophic cost, the Prime Minister of India has announced an ambitious plan to eliminate the TB in India by 2025, 5 years ahead of UN targets by ensuring quality health care and advanced treatment. Responding to the challenge of TB and drug-resistant tuberculosis, WHO is regularly issuing evidence-based guidelines using the International Grading of Recommendations Assessment, Development and Evaluation approach to assessment of new scientific evidence. Major advances have been reported in newer drugs and impact making research for new regimens in recent years. National Tuberculosis Elimination Programme has adopted effective interventions and technologies for diagnosis, treatment, and care of TB giving a new hope for elimination of TB. The present article reviews the new impact making research transforming traditional 18 to 24 months treatment of MDR/XDR TB to 6 months treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.